COVID-19 Vaccine & Treatment Research | NYU Langone Health

Skip to Main Content
Vaccine Center Research COVID-19 Vaccine & Treatment Research

COVID-19 Vaccine & Treatment Research

Researchers in the Vaccine Center have led NYU Langone’s efforts to develop new vaccines and treatments for COVID-19.

Since spring 2020, our researchers have partnered with major pharmaceutical companies to participate in COVID-19–related clinical trials to test vaccines and antibody therapy.

As a National Institute of Allergy and Infectious Diseases (NIAID)–designated Vaccine and Treatment Evaluation Unit (VTEU), the Vaccine Center has also been participating in multiple studies to help NIAID’s effort to develop vaccines and treatments against SARS-CoV-2 infection, which causes COVID-19.

Pfizer–BioNTech mRNA Vaccine Trials

The Vaccine Center was the sentinel site of this trial, enrolling the first phase 1 study participant to receive experimental Pfizer–BioNTech messenger RNA (mRNA) to prevent SARS-CoV-2 infection. The Vaccine Center has since continued to participate in phase 2/3 trials with Pfizer and has been recruiting participants to study booster doses.

Read an interview with our first phase 1 Pfizer–BioNTech participant, who reflects on her experience two years later.

Read our paper in Nature describing the Pfizer/BioNTech vaccine trial.

VIDEO: Infectious diseases expert Dr. Mark J. Mulligan discusses the phase 2/3 clinical trial that tests the efficacy of a COVID-19 vaccine candidate.

AZD1222 COVID-19 Vaccine Trial

Our five sites (660 First Avenue in Manhattan, NYU Langone Hospital—Brooklyn, NYU Langone Hospital—Long Island, NYC Health + Hospitals/Bellevue, and VA NY Harbor Healthcare System) participated in an international double-blind, randomized, placebo-controlled phase 3 clinical trial to investigate vaccine efficacy and immunogenicity of two doses of AZD1222.

Read more from our study in The New England Journal of Medicine on how the data from this trial demonstrated that AZD1222 was safe and efficacious in preventing COVID-19 in large, diverse, at-risk populations, as well as the most recent results published in the Journal of Clinical Investigation.

Heterologous Prime Boosts: The “Mix and Match” Study

Vaccine Center sites at NYU Langone Hospital—Long Island and NYC Health + Hospitals/Bellevue participated in the National Institutes of Health–funded “Mix and Match” study—a SARS-CoV-2 vaccine booster trial—the results of which directly influenced Centers for Disease Control and Prevention (CDC) guidelines on booster vaccines.

Read more about the results of this study in The New England Journal of Medicine and Cell Report Medicine.

SARS-CoV-2 Vaccines in Pregnancy and Postpartum: The MOMI-VAX Study

The Vaccine Center sites at 660 First Avenue and NYU Langone Hospital—Brooklyn participated in an observational study to evaluate the development and durability of COVID-19 antibodies in individuals who receive, or who already have received, a COVID-19 vaccine while pregnant or during the first two months postpartum. Additionally, the study assessed the transfer of antibodies to infants across the placenta and through breast milk. The results from this study showed that COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses as well as transplacental antibody transfer to the newborn.

Read about this trial in an NIH/NIAID news release and learn more about the trial results.

Prior History of COVID-19 Influences Adaptive Immune Responses to mRNA Vaccination

Teams working with Ramin Herati, MD, and Mark J. Mulligan, MD, compared the COVID-19 vaccine immune responses of participants who had experienced COVID-19 infection to those who did not. Their work stressed the relevance of immunological history for understanding COVID-19 vaccine immune responses and has important implications for personalizing mRNA vaccination regimens and the deployment of booster shots.

Read more about this study in Science Translational Medicine.

The Neutralizing Antibody LY-CoV555 Treatment Against SARS-CoV-2 Infection

In Spring 2020, the Mulligan Lab and the lab of Meike Dittmann, PhD, helped support Eli Lilly search for new promising therapeutic options for individuals with COVID-19 by testing their monoclonal antibodies candidates against live virus in vitro. A few weeks later, the Vaccine Center enrolled the first participant in a phase 1 clinical trial to test LY-CoV555, a monoclonal antibody designed to treat patients hospitalized due to infection with SARS-CoV-2.

Read more about this work in Science Translational Medicine.

REGEN-COV Antibody Trial to Prevent Covid-19

Our team at 660 First Avenue participated in a trial assessing the efficacy and safety combination of the monoclonal antibodies casirivimab and imdevimab to prevent SARS-CoV-2 infection in people who had household contact with individuals with a positive SARS-CoV-2 RT-PCR. The study showed that the treatment prevented symptomatic COVID-19 and asymptomatic SARS-CoV-2 infection and reduced the duration of symptomatic disease among participants who became infected.

Read more about this study in JAMA Network and in The New England Journal of Medicine.

Participate in a COVID-19 Clinical Trial

We are actively recruiting participants for our COVID-19 clinical trials. Learn more about how to participate.